Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 9/2014

01-09-2014 | Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema

Authors: Marcus A. Bearse Jr., Glen Y. Ozawa

Published in: Current Diabetes Reports | Issue 9/2014

Login to get access

Abstract

In this review article, we first present a brief overview of the vascular and neural components of diabetic retinopathy. Next, the multifocal electroretinogram (mfERG) technique, which can map neuroretinal function noninvasively, is described. Findings in diabetic retinal disease using the mfERG are reviewed. We then describe the progress that has been made to predict the onset and progression of diabetic retinopathy and edema in specific retinal locations, using quantitative models based on the mfERG. Finally, we consider the implications for the future of these predictive models.
Literature
1.
National Society to Prevent Blindness. Visual problems in the U.S. definitions, data sources, detailed data tables, analyses, interpretation. New York: National Society to Prevent Blindness; 1980. p. 1–46.
2.
Beckles GL, Chou CF. Diabetes - United States, 2006 and 2010. MMWR Surveill Summ. 2013;62 Suppl 3:99–104.PubMed
3.
Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003 [database on the Internet]. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2004. Available from: http://​www.​cdc.​gov/​diabetes/​pubs/​pdf/​ndfs_​2003.​pdf. Accessed 8 Apr 2005.
4.
Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes and prediabetes in the United States, 2011 [database on the Internet]. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2011. Available from: http://​www.​cdc.​gov/​diabetes/​pubs/​pdf/​ndfs_​2011.​pdf. Accessed 1 Apr 2014.
5.
The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–20.CrossRef
6.
Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156–63.PubMedCrossRef
7.
UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–13.CrossRef
8.
Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601–8.PubMedCrossRef
9.
Cunha-Vaz J, Bernardes R. Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog Retin Eye Res. 2005;24:355–77.PubMedCrossRef
10.
Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris 3rd FL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143–56.PubMed
11.
Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98:823–33.CrossRef
12.
Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796–806.CrossRef
13.
Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283–90.PubMedCrossRef
14.
Wolter JR. Diabetic retinopathy. Am J Ophthalmol. 1961;51:1123–41.PubMed
15.
Bresnick GH. Diabetic retinopathy viewed as a neurosensory disorder. Arch Ophthalmol. 1986;104:989–90.PubMedCrossRef
16.
Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53–60.PubMedCrossRef
17.
Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401–11.PubMedCrossRef
18.
Jackson GR, Barber AJ. Visual dysfunction associated with diabetic retinopathy. Curr Diab Rep. 2010;10:380–4.PubMedCrossRef
19.
20.
Sutter EE, Tran D. The field topography of ERG components in man–I. The photopic luminance response. Vis Res. 1992;32:433–46.PubMedCrossRef
21.
Kondo M, Miyake Y, Horiguchi M, Suzuki S, Tanikawa A. Clinical evaluation of multifocal electroretinogram. Invest Ophthalmol Vis Sci. 1995;36:2146–50.PubMed
22.
Bearse Jr MA, Sutter EE. Imaging localized retinal dysfunction with the multifocal electroretinogram. J Opt Soc Am A Opt Image Sci Vis. 1996;13:634–40.PubMedCrossRef
23.
24.
Sutter EE. Imaging visual function with the multifocal m-sequence technique. Vis Res. 2001;41:1241–55.PubMedCrossRef
25.
Hood DC. Assessing retinal function with the multifocal technique. Prog Retin Eye Res. 2000;19:607–46.PubMedCrossRef
26.
27.
Sutter EE, Bearse Jr MA. The optic nerve head component of the human ERG. Vis Res. 1999;39:419–36.PubMedCrossRef
28.
Bearse Jr MA, Shimada Y, Sutter EE. Distribution of oscillatory components in the central retina. Doc Ophthalmol. 2000;100:185–205.PubMedCrossRef
29.
Hood DC, Bearse Jr MA, Sutter EE, Viswanathan S, Frishman LJ. The optic nerve head component of the monkey's (Macaca mulatta) multifocal electroretinogram (mERG). Vis Res. 2001;41:2029–41.PubMedCrossRef
30.
Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci. 2002;43:1673–85.PubMed
31.
Hare WA, Ton H. Effects of APB, PDA, and TTX on ERG responses recorded using both multifocal and conventional methods in monkey. Effects of APB, PDA, and TTX on monkey ERG responses. Doc Ophthalmol. 2002;105:189–222.PubMedCrossRef
32.
Bearse Jr MA, Han Y, Schneck ME, Barez S, Jacobsen C, Adams AJ. Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:3259–65.PubMedCrossRef
33.
Shimada Y, Bearse Jr MA, Sutter EE. Multifocal electroretinograms combined with periodic flashes: direct responses and induced components. Graefes Arch Clin Exp Ophthalmol. 2005;243:132–41.PubMedCrossRef
34.
Bronson-Castain KW, Bearse Jr MA, Han Y, Schneck ME, Barez S, Adams AJ. Association between multifocal ERG implicit time delays and adaptation in patients with diabetes. Invest Ophthalmol Vis Sci. 2007;48:5250–6.PubMedCentralPubMedCrossRef
35.
Palmowski AM, Sutter EE, Bearse Jr MA, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci. 1997;38:2586–96.PubMed
36.
Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2638–51.PubMed
37.
Hood DC, Li J. A technique for measuring individual multifocal ERG records. In: Yager D, editor. Non-invasive assessment of the visual system. Trends in optics and photonics, vol. 11. Washington, D.C.: Optical Society of America; 1997. p. 33–41.
38.
Han Y, Bearse Jr MA, Schneck ME, Barez S, Jacobsen C, Adams AJ. Towards optimal filtering of "standard" multifocal electroretinogram (mfERG) recordings: findings in normal and diabetic subjects. Br J Ophthalmol. 2004;88:543–50.PubMedCentralPubMedCrossRef
39.
Bearse Jr MA, Han Y, Schneck ME, Adams AJ. Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram. Invest Ophthalmol Vis Sci. 2004;45:296–304.PubMedCrossRef
40.
Bearse Jr MA, Adams AJ, Han Y, Schneck ME, Ng J, Bronson-Castain K, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res. 2006;25:425–48.PubMedCentralPubMedCrossRef
41.
Klemp K, Larsen M, Sander B, Vaag A, Brockhoff PB, Lund-Andersen H. Effect of short-term hyperglycemia on multifocal electroretinogram in diabetic patients without retinopathy. Invest Ophthalmol Vis Sci. 2004;45:3812–9.PubMedCrossRef
42.
Yu M, Zhang X, Zhong X, Yu Q, Jiang F, Ma J, et al. Multifocal electroretinograms in the early stages of diabetic retinopathy. Chin Med J (Engl). 2002;115:563–6.
43.
Kurtenbach A, Langrova H, Zrenner E. Multifocal oscillatory potentials in type 1 diabetes without retinopathy. Invest Ophthalmol Vis Sci. 2000;41:3234–41.PubMed
44.
Yamamoto S, Yamamoto T, Hayashi M, Takeuchi S. Morphological and functional analyses of diabetic macular edema by optical coherence tomography and multifocal electroretinograms. Graefes Arch Clin Exp Ophthalmol. 2001;239:96–101.PubMedCrossRef
45.
Shimada Y, Li Y, Bearse Jr MA, Sutter EE, Fung W. Assessment of early retinal changes in diabetes using a new multifocal ERG protocol. Br J Ophthalmol. 2001;85:414–9.PubMedCentralPubMedCrossRef
46.
Onozu H, Yamamoto S. Oscillatory potentials of multifocal electroretinogram retinopathy. Doc Ophthalmol. 2003;106:327–32.PubMedCrossRef
47.
Tyrberg M, Ponjavic V, Lovestam-Adrian M. Multifocal electroretinography (mfERG) in insulin dependent diabetics with and without clinically apparent retinopathy. Doc Ophthalmol. 2005;110:137–43.PubMedCrossRef
48.
Klemp K, Sander B, Brockhoff PB, Vaag A, Lund-Andersen H, Larsen M. The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. Invest Ophthalmol Vis Sci. 2005;46:2620–6.PubMedCrossRef
49.
Han Y, Adams AJ, Bearse Jr MA, Schneck ME. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol. 2004;122:1809–15.PubMedCrossRef
50.
Schneck ME, Bearse Jr MA, Han Y, Barez S, Jacobsen C, Adams AJ. Comparison of mfERG waveform components and implicit time measurement techniques for detecting functional change in early diabetic eye disease. Doc Ophthalmol. 2004;108:223–30.PubMedCrossRef
51.
Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE. The nature and extent of retinal dysfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci. 2000;41:3643–54.PubMed
52.
Holm K, Ponjavic V, Lovestam-Adrian M. Using multifocal electroretinography hard exudates affect macular function in eyes with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:1241–7.PubMedCrossRef
53.
Lovestam-Adrian M, Holm K. Multifocal electroretinography amplitudes increase after photocoagulation in areas with increased retinal thickness and hard exudates. Acta Ophthalmol. 2010;88:188–92.PubMedCrossRef
54.
Greenstein VC, Chen H, Hood DC, Holopigian K, Seiple W, Carr RE. Retinal function in diabetic macular edema after focal laser photocoagulation. Invest Ophthalmol Vis Sci. 2000;41:3655–64.PubMed
55.
Tan W, Wright T, Dupuis A, Lakhani E, Westall C. Localizing functional damage in the neural retina of adolescents and young adults with type 1 diabetes. Invest Ophthalmol Vis Sci. 2014.
56.
Lakhani E, Wright T, Abdolell M, Westall C. Multifocal ERG defects associated with insufficient long-term glycemic control in adolescents with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:5297–303.PubMedCrossRef
57.•
Bronson-Castain KW, Bearse Jr MA, Neuville J, Jonasdottir S, King-Hooper B, Barez S, et al. Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. Retina. 2012;32:92–102. The results of this study indicate that adolescents with type 2 diabetes have greater dysfunction and vascular changes in the retina of the eye than adolescents with type 1 diabetes.PubMedCentralPubMedCrossRef
58.
Laron M, Bearse Jr MA, Bronson-Castain K, Jonasdottir S, King-Hooper B, Barez S, et al. Interocular symmetry of abnormal multifocal electroretinograms in adolescents with diabetes and no retinopathy. Invest Ophthalmol Vis Sci. 2012;53:316–21.PubMedCentralPubMedCrossRef
59.
Bronson-Castain KW, Bearse Jr MA, Neuville J, Jonasdottir S, King-Hooper B, Barez S, et al. Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina. 2009;29:618–26.PubMedCentralPubMedCrossRef
60.
Tyrberg M, Lindblad U, Melander A, Lovestam-Adrian M, Ponjavic V, Andreasson S. Electrophysiological studies in newly onset type 2 diabetes without visible vascular retinopathy. Doc Ophthalmol. 2011;123:193–8.PubMedCrossRef
61.•
Laron M, Bearse Jr MA, Bronson-Castain K, Jonasdottir S, King-Hooper B, Barez S, et al. Association between local neuroretinal function and control of adolescent type 1 diabetes. Invest Ophthalmol Vis Sci. 2012;53:7071–6. The findings reported here show, in adolescents with type 1 diabetes, that there is a correlation between long-term blood glucose concentration (HbA1c) and neuroretinal function measured with the mfERG.PubMedCentralPubMedCrossRef
62.•
Dhamdhere KP, Bearse Jr MA, Harrison W, Barez S, Schneck ME, Adams AJ. Associations between local retinal thickness and function in early diabetes. Invest Ophthalmol Vis Sci. 2012;53:6122–8. This paper describes the lack of association, in patients with diabetes and no retinopathy, between local retinal function measured with the mfERG and changes in total retinal thickness. The functional changes do not appear to have a measureable anatomical correlate.PubMedCentralPubMedCrossRef
63.
Han Y, Bearse Jr MA, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:948–54.PubMedCrossRef
64.
Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049–60.PubMedCrossRef
65.
Ng JS, Bearse Jr MA, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci. 2008;49:1622–8.PubMedCrossRef
66.
Han Y, Schneck ME, Bearse Jr MA, Barez S, Jacobsen CH, Jewell NP, et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:4106–12.PubMedCrossRef
67.••
Harrison WW, Bearse Jr MA, Ng JS, Jewell NP, Barez S, Burger D, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:772–7. This paper describes the first model based on the mfERG to predict the initial onset of diabetic retinopathy in adults. The model was cross-validated and demonstrates impressive accuracy.PubMedCentralPubMedCrossRef
68.••
Harrison WW, Bearse Jr MA, Schneck ME, Wolff BE, Jewell NP, Barez S, et al. Prediction, by retinal location, of the onset of diabetic edema in patients with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:6825–31. This report describes the formulation of the first mfERG-based model to predict the onset of diabetic retinal edema in adults. The cross-validated model demonstrates impressive accuracy.PubMedCentralPubMedCrossRef
Metadata
Title
Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema
Authors
Marcus A. Bearse Jr.
Glen Y. Ozawa
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 9/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0526-9

Other articles of this Issue 9/2014

Current Diabetes Reports 9/2014 Go to the issue

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Interleukin-7 and Type 1 Diabetes

Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Low-Protein Diet for Diabetic Nephropathy

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Metabolic Abnormalities in the Pathogenesis of Type 1 Diabetes

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Managing Sedentary Behavior to Reduce the Risk of Diabetes and Cardiovascular Disease

Psychosocial Aspects (KK Hood, Section Editor)

Young Children with Type 1 Diabetes: Challenges, Research, and Future Directions

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Self-Antigen Expression in the Peripheral Immune System: Roles in Self-Tolerance and Type 1 Diabetes Pathogenesis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits